Assessing cost-effectiveness in the management of multiple sclerosis

Ceri J Phillips
Ioan Humphreys
Institute for Health Research, School of Health Science, Swansea University, Swansea, Wales, UK

Abstract: Multiple sclerosis (MS) is one of the most common causes of neurological disability in young and middle-aged adults, with current prevalence rates estimated to be 30 per 100,000 populations. Women are approximately twice as susceptible as males, but males are more likely to have progressive disease. The onset of the disease normally occurs between 20 and 40 years of age, with a peak incidence during the late twenties and early thirties, resulting in many years of disability for a large proportion of patients, many of whom require wheelchairs and some nursing home or hospital care. The aim of this study is to update a previous review which considered the cost-effectiveness of disease-modifying drugs (DMDs), such as interferons and glatiramer acetate, with more up to date therapies, such as mitaxantrone hydrochloride and natalizumab in the treatment of MS. The development and availability of new agents has been accompanied by an increased optimism that treatment regimens for MS would be more effective; that the number, severity and duration of relapses would diminish; that disease progression would be delayed; and that disability accumulation would be reduced. However, doubts have been expressed about the effectiveness of these treatments, which has only served to compound the problems associated with endeavors to estimate the relative cost-effectiveness of such interventions.

Keywords: multiple sclerosis, disease management, immunomodulatory drugs, cost-effectiveness, cost-effectiveness analysis, cost-utility analysis

Multiple sclerosis: the context

Introduction

Multiple sclerosis (MS) is believed to affect more than 1 million people worldwide¹ and is one of the most common causes of neurological disability in young and middle-aged adults.²–⁴ Prevalence rates vary considerably, though recent estimates put the global prevalence at any one time at 30 per 100,000 population,⁵ with rates highest in northern parts of Europe, southern Australia and the middle part of North America. Women are approximately twice as susceptible as males,²,⁶,⁷ but males are more likely to have progressive disease from onset.⁸,⁹ The onset of the disease normally occurs between 20 and 40 years of age, with a peak incidence during the late twenties and early thirties.¹⁰,¹¹ The relatively early age of onset results in many years of disability for a large proportion of patients, many of whom require wheelchairs and some nursing home or hospital care.¹²

While the cause and pathogenesis of MS are unknown, it is believed to be primarily an inflammatory condition in which autoimmune attack is associated with breakdown of the normal barrier separating blood from the brain. This leads to the destruction of myelin sheaths that normally facilitate nerve conduction. Although many episodes may be asymptomatic, the central nervous system has a limited capacity to repair areas of...
demyelination and repeated inflammatory attack often leads to scarring and loss of nerve cells themselves. It is the scarring and neuronal loss that probably underlie many of the chronic symptoms associated with MS, including limitation of mobility, ataxia, spasticity, pain, cognitive dysfunction and mood disturbance.13 MS is a diverse disease initially characterized, in most cases, by recurrent attacks of neurological dysfunction (relapses) followed by periods of complete or incomplete recovery (remissions). If recovery from relapses is incomplete, there will be stepwise increases in disability. This is relapsing-remitting MS (RRMS) and accounts for between 65% and 85% of cases at onset.13-15 However, within 10 years about 50% develop the secondary progressive form of the disease, SPMS.16 Approximately 15% of patients experience progressive MS from the outset with unrelenting advancement of the disease and maximum disability ensuing within months or over several years,16 while a small proportion have a benign course with minimal disability after 10 to 15 years.13 For those with RRMS, relapses occur unexpectedly, with symptoms appearing over a few hours and maximum recovery, although not necessarily complete, usually taking several weeks. Typically, relapses may involve visual disturbance (eg, blurred or double vision), sensory problems (numbness, tingling and pain), limb weakness or paralysis, or any combination of the above. On rare occasions, more serious relapses can occur involving life-threatening emergencies such as brain stem inflammation leading to total paralysis and respiratory failure.

The cost of multiple sclerosis
A number of studies have attempted to assess the costs of MS.15,17-46 These have provided a wealth of information, but a variable picture emerges as to what constitutes the total cost of care. The full economic cost of MS is substantial, given that patients experience a major perturbation in their daily activities and the disease mainly affects young people, who are obliged to restrict their levels of economic activity, either temporarily or permanently.16 A review of the literature demonstrated that positive relationships exist between some components of the direct costs of the disease and indirect costs – the largest element of the cost of the disease.29 Studies have also shown that the total costs for patients increase with disability, as measured by the Expanded Disability Status Scale (EDSS).47 The EDSS scale is an instrument rating elements of neurological impairment, based upon an elaboration of the standard neurological examination. The scale ranges from 0 (no impairment) to 10 (death from MS).

A 2005 Swedish study by Kobelt et al46 produced per patient total costs of €27,254 for mild MS (EDSS ≤ 2.0) and €52,457 for patients with severe MS (EDSS ≥ 6.5) (Figure 1). This study represents one of the largest undertaken in terms of the number of patients included (n = 2048). The major direct cost driver in the UK was ambulatory care, which the authors put down to high DMD usage in the UK, thus increasing outpatient visits to neurologists. Indirect costs at EDSS ≤ 2.0 were calculated to be €10,142. However they double as disease severity increases to EDSS ≥ 6.5 (€20,545). This is mainly put down to the employment status of the patient (high levels of early retirement) which in turn increased the costs of informal care (EDSS ≥ 6.5 (€18,382).46 Indirect costs tend to be the largest component of the overall cost burden in MS,15,17,21,22,27,31,33-46 due to patients having to leave the labor market because of their disability and carers also having to leave employment situations to provide the necessary support and care.26 The question of whether the costs associated with informal care provided by friends and relatives should be included remains unclear, as they are difficult to quantify and value.17 It is accepted that specific inputs to the care process provided by informal carers should be included in direct costs, but the issue of whether production losses resulting from such care inputs should be included remains contentious.

The impact of MS on quality of life has also received considerable attention. The most common symptoms associated with MS include motor weakness, spasticity, sensory impairment, ataxia, tremor, nystagmus, dysarthria, vision changes, depression, cognitive abnormalities, fatigue, and bowel, bladder and sexual dysfunction. In addition, patients may also experience secondary complications such as urinary tract infections, respiratory infections, decubiti and muscle contractures.29 These primary and secondary symptoms result in people with MS suffering marked reductions in their quality of life (QOL), both during the early phases of the disease and as it increasingly impacts on levels of disability.17,48-52 Relapses have a particularly devastating effect on patients lives, since relapses are unpredictable in terms of timing, duration and severity, and therefore restrict patients ability to plan their lives, especially for major events such as holidays and family celebrations.52 While MS has an impact on all members of the family, the major responsibilities for care tends to rest with the primary carer – in most cases the spouse – who has to adopt other functions and responsibilities, including wage earner, homemaker, primary

---

*Currencies have been reported in Euros and the specific currency used in the study. Conversion of currencies was calculated for the 1 January of the currency rate year stated by the author. Every effort has been made to maintain the accuracy and integrity of the original estimate.
parent as well as carer. The physical, mental and financial burdens placed on carers are often significant and can lead to stress, fatigue and depression and, in many cases, the quality of life of the carer reflects that of the patient.

The next section outlines the aim and objectives of this review and describes the approaches adopted in the collection and assessment of relevant studies.

**Purpose of study and methods employed**

The aim of this study is to examine the approaches used to assess the cost-effectiveness of disease modifying therapies in the treatment of MS such as interferons and glatiramer acetate, and to include recent additions to the formulary such as mitaxantrone hydrochloride (MH) and natalizumab in the treatment of MS. Electronic databases including Medline and Pubmed were searched for studies on the cost-effectiveness of interventions in the field of MS. Additional studies identified through searching bibliographies of related publications and using the Google internet search function. Included studies were assessed using standard critical appraisal criteria. Search terms were: Multiple Sclerosis, Disease management, Immunomodulatory drugs, Cost-Effectiveness, Cost-Effectiveness Analysis, Quality of life, Economic Evaluation, Cost Analysis, Cost benefit, Cost-utility, cost-utility analysis, Cost minimization, Pharmacoeconomics.

**Inclusion criteria**

- Language of publication restricted to English.
- Studies that focused on the diagnosis, prevention and or treatment of MS and reported a synthesis of associated costs and benefits.
- Studies that compared treatment with immunomodulatory drugs; and used patient based outcomes such as relapses, disease progression, and side effects.
- Studies restricted by date of conversion rates pre 1999.
- Studies published in a peer reviewed journal.

**Exclusion criteria**

- Non-English language publications
- Abstracts presented at conferences
- Studies not available in full text.

Studies were excluded if they did not conform, in the main, to the recognized conventions for health economic appraisals, but some of these provided useful contextual information for this review.

The next section examines the range of available therapies available for the treatment of MS and provides an overview of the discussions relating to the relative effectiveness of such interventions.

**The clinical effectiveness of treatments in MS**

It has been argued that the management of patients with MS should begin at the time of diagnosis. There are three aspects to the management of MS:

- the prevention of disease progression and relapse rates;
- the treatment of acute exacerbations;
- the treatment of chronic symptoms.

Prior to the advent of disease-modifying drugs (DMDs), the mainstay of MS therapy was symptomatic treatment (both physical and pharmacological) and this still remains a central tenet of patient management in conjunction with

![Figure 1 Costs (Euros) of multiple sclerosis by disease severity, UK 2005.](https://www.dovepress.com/)

**Abbreviation:** EDSS, Expanded Disability Status Scale.
disease-modifying therapy. Steroids are the treatment for acute exacerbations, but these do not affect consequent disability, while chronic symptoms are treated by physiotherapy and anti-spasticity drugs, and fatigue by psychological and physiological treatments and by neurorehabilitation.\textsuperscript{13} Counseling is also important and may be given by health professionals or more informally through patient support groups and MS charities. However, the quality and scope of therapies and services available to sufferers of MS differ widely within countries and across countries.\textsuperscript{32,57}

In relation to RRMS, the goals of treatment ideally are to:\textsuperscript{12,58,59}

- treat acute relapses;
- improve health-related quality of life;
- reduce the frequency and severity of relapses;
- delay disability accumulation; and
- postpone the onset of the progressive phase of the disease.

The development and availability of DMDs was accompanied by an increased optimism that the above goals could be achieved, and these technologies have been approved by a number of regulatory authorities for use in the treatment of MS.

Evidence from randomized controlled trials\textsuperscript{60–72} suggest that interferons, as a class, reduce both relapse rate and severity, and also delay the progression of disability especially in relapse remitting MS. There is also a marked and rapid reduction in MS disease activity, as measured by repeated brain magnetic resonance imaging (MRI) scans.\textsuperscript{12,73} However, doubts have continued to be expressed about the validity of such evidence and the extent to which interferons are effective\textsuperscript{3,13} and the extent of their benefits relative to side effects and costs.\textsuperscript{74} In addition to the clinical trials of interferons in MS, a number of reviews have aimed to assess the effectiveness of these therapeutic interventions\textsuperscript{3,13,58,75–83} but arriving at a consensus has been problematic due to the methodological quality of trials undertaken.\textsuperscript{3,79,84,85} It has been argued that “well conducted trials using outcome measures with clinical significance for groups of patients with different types of multiple sclerosis and long term follow up are needed if the evidence base of treatment for the disease is to be improved.”\textsuperscript{85}

Glatiramer acetate consists of a random mixture of four naturally occurring amino acids, which was initially developed to mimic myelin basic protein, one of the antigens thought to be involved in the pathogenesis of MS.\textsuperscript{86} It has a different mechanism of action to that of the interferons and appears to have a more favorable tolerability profile,\textsuperscript{59,87} but has an efficacy profile broadly similar to that of the interferons.\textsuperscript{87} In a review of its effectiveness, it was concluded that the extent of benefits were not clear,\textsuperscript{13} while studies which have reported on the follow-up long term effects of glatiramer acetate,\textsuperscript{87,88} have also been confronted with methodological issues, which have tended to cloud the quality of these studies.\textsuperscript{87} The 2008 REGARD study\textsuperscript{89} which compared the use of interferon beta-1a (IFN\textbeta-1a) (Rebif\textsuperscript{®}) and glatiramer acetate in patients with RRMS, found that with the outcome measure tested – time to first relapse – there was no significant difference between the two treatment groups. However, the authors acknowledged that “the ability to predict clinical superiority in a head to head study on the basis of results from separate placebo-controlled studies of each drug might be restricted and is challenged by a trial population with low disease activity”.

MH acts to “damage” rapidly dividing cells, such as those in the immune system and is usually used, in combination with other drugs, as a type of chemotherapy to treat certain types of cancer. In recent years it has also been used to treat very active RMSS or SPMS. During the period of treatment, mitoxantrone appears to work in MS by suppressing the immune system and giving the nervous system a chance to recover from recent relapses.\textsuperscript{90} MH was licensed for the treatment of MS in October 2000 by the Food and Drug Administration (FDA), but it is not licensed in some other countries for the treatment of MS and is used as an “off-licence” treatment for MS.\textsuperscript{90} According to the MIMS study,\textsuperscript{91} the high dose of MH (12 mg/m\textsuperscript{2} every 3 months for up to 24 months) was “effective and generally well tolerated, and significant treatment effects were found by all of the outcome measures”.\textsuperscript{91} Although beneficial effects were also observed with the low-dose drug when compared to placebo, they were not as convincing as with the higher dose. The authors believed that “mitoxantrone provides a new therapeutic option for people with worsening relapsing remitting MS, or secondary progressive MS”.\textsuperscript{91}

Natalizumab is a monotherapy DMD approved for use by the FDA and the European Union (EU) in June 2006. It is one of the more recent additions for treatment in MS. It is thought that natalizumab exerts its therapeutic efficacy by blocking the pass of T cells, a specific immune cell which plays a major role in the pathogenesis of MS, through the blood–brain barrier, thus preventing these cells reach the central nervous system.\textsuperscript{90} Natalizumab is currently licensed as a single disease modifying therapy for 2 subgroups of highly active relapsing-remitting multiple sclerosis (HARRMS) sufferers and are classed as: “patients who have had 2 or more relapses with one or more gadolinium enhancing
lesions on brain MRI or a significant increase in T2 lesion load compared with a recent MRI and patients who have failed to respond to a full and adequate course of interferon b. Patients should have had at least one relapse in the previous year while on therapy, and have at least nine T2-hyperintense lesions in cranial MRI or at least one gadolinium-enhancing lesion. Results from the clinical effectiveness AFFIRM trial are very favorable, with Natalizumab reducing the risk of sustained progression of disability by 42%, with the cumulative probability of progression being 17% compared to 29% in the placebo group. The rate of relapses was reduced by 68% and led to an 82% reduction in the accumulation of new or enlarged hyperintense lesions. Natalizumab costs £1,130 (€1,167) per 300 mg vial, with an annual cost of approximately £14,730 (€15,214) per patient (excluding hospital outpatient costs).

The result of this uncertainty surrounding the effectiveness of these disease therapies in the treatment of MS has compounded the problems associated with endeavors to estimate the relative cost-effectiveness of such interventions.

The cost-effectiveness of DMDs in MS

In addition to the uncertainties associated with the clinical effectiveness, there are a number of issues that have resulted in a wide range of estimates of cost-effectiveness and hampered attempts to establish any consensus relating to the cost-effectiveness of DMDs. These issues relate to the appropriateness of the data used from the trials, the natural history or epidemiological data used to extrapolate to longer time horizons and the structure of models used. Methodological issues relating to the nature, derivation and quality of data used to populate the models and specific inclusion and exclusion criteria in terms of parameter selection can often render any estimations of cost-effectiveness less than robust.

While, increasing use has been made of Markov models, which allow for the management of patients in and between different health states over time, to assess the relative cost effectiveness of DMDs in MS, problems are still too readily apparent. The timescales involved frequently extend beyond the duration of clinical trials developed to assess clinical effects, and there is a lack of consensus as to the longer-term effects of DMDs. The wide range of estimates reflects the difficulties inherent in translating the results from clinical trials into models that assess the cost-effectiveness of interventions in MS, while the lack of homogeneity in study design also contributes to the wide variation in the estimates of cost-effectiveness and the difficulty of arriving at a consensus. Short-term analyses avoid the problems of attempting to extrapolate from clinical data, but fail to do justice to the duration of the illness and its progression over time, while longer-term studies may capture the longer-term effects, but do so with only limited evidence to substantiate the extrapolations from relatively short-term data and the assumptions underlying the construction of the models (for a full list of studies see Table 1). For example, efficacy data from the EVIDENCE trial which lasted for 64 weeks was utilized in a model that simulated effects for a 4-year period. Guo explained that the relatively short modeling timeframe was used to give consistency to “many US Payers realistic time horizon”, and also to maintain analytical relevance with the likelihood of newer IFNβ-1a treatments becoming available during the projected time span. Further, clinical trial data from the IFNβ-1b Study is utilized 9 times in various studies and, while, the trial lasted for 3 years, models have been developed that cover timeframes of 10 years up to 40 years.

However, recent studies have generally produced more favorable cost-effectiveness ratios, benefiting from more relevant and up-to-date data relating to disease progression and it may be reasonable to conclude that the cost-effectiveness of interventions improves when longer time perspectives are employed, and the models more accurately reflect the progression of disease experienced by patients. As well as the time horizon, the estimates are highly sensitive to the approach taken to discounting costs and benefits; the cost of the therapies; the costs of patient management; disease progression, with and without treatment, and what happens to patients when they stop treatment; the impact of MS on carers in terms of utility loss and costs incurred; the effect of non-responders and adverse events associated with the therapies; the relationship between disability levels and utility losses and the extent to which indirect costs are included.

In addition, the assignment of utility scores to various “states” in MS have proved to be very contentious. These states are often founded on EDSS, but concerns relating to its large inter-rater reliability, its ordinal nature and its unnecessary focus on certain categories of functional impairment have led to questions being posed regarding the validity of results derived from its use. The utility values attached to each of the EDSS states have varied considerably. It has been estimated that the difference between EDSS state 0 and 3.0 represents a 30% reduction in a patient’s quality of life, a similar reduction in quality of life from state 3.0 to state 7.0, while states 9.0 (helpless bed patient; can communicate and eat)
<table>
<thead>
<tr>
<th>Author</th>
<th>Intervention and disease category</th>
<th>Design, methods and timescales</th>
<th>Cost per QALY estimate</th>
<th>Sensitivity analysis (best-case and worse-case scenarios)</th>
<th>Perspective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bose et al</td>
<td>Glatiramer acetate in RRMS</td>
<td>Decision analytic model based on patient level data from pivotal clinical trial for 6 and 8 years</td>
<td>$45,992 (£52,864) (6 years) $36,429 (£41,872) (8 years)</td>
<td>Doubling the cost of relapse – Cost per QALY $28,602 ($32,875) (8 years) Duration of relapse (1 month rather than 2 months) – Cost per QALY $136,350 (£156,724)</td>
<td>Healthcare sector</td>
</tr>
<tr>
<td>Chilcott et al</td>
<td>IFNβ and glatiramer acetate in RRMS and SPMS</td>
<td>Markov model simulating the clinical progression of MS over 20 years</td>
<td>$67,808 (£77,940) to $157,477 (£181,009) (depending on therapy and dosage)</td>
<td>Probability that the cost-effectiveness of any of the interventions is better than $32,258 (£37,078) is between 3% and 18%</td>
<td>Healthcare sector</td>
</tr>
<tr>
<td>Kobelt et al</td>
<td>IFNβ-1b in SPMS</td>
<td>Markov model simulating the clinical progression of MS over 10 years using 3-year clinical trial data and then extrapolating</td>
<td>$39,250 (£45,115) (all costs included and discounted at 3%)</td>
<td>$62,100 (£71,379) excluding indirect costs</td>
<td>Societal</td>
</tr>
<tr>
<td>Kobelt et al</td>
<td>IFNβ-1b in SPMS</td>
<td>Markov model simulating the clinical progression of MS using 3-year clinical trial data and then natural history disease data up to 10 years</td>
<td>$25,700 (£29,540) (all costs included and discounted at 3%)</td>
<td>$44,700 (£51,379) excluding indirect costs</td>
<td>Societal</td>
</tr>
<tr>
<td>Kobelt et al</td>
<td>IFNβ-1b in RRMS and SPMS</td>
<td>Markov model simulating the clinical progression of MS using 3-year clinical trial data from both RRMS and SPMS studies and then natural history disease data up to 10 years</td>
<td>$6,786 (£7,800) for 3 years treatment (all costs included and discounted at 3%)</td>
<td>Probability that the cost per QALY over a 20-year time frame is below $43,500 (£50,000) for patients starting treatment at EDSS3.0 is 80%</td>
<td>Healthcare sector + societal</td>
</tr>
<tr>
<td>Phillips et al</td>
<td>IFNβ-1b in RRMS</td>
<td>Markov model to mirror disease progression and take into account the number, severity and duration of relapses; the probability of becoming disabled; the speed at which people with MS become disabled; the different costs associated with each level of disability; the different health states experienced by patients with each level of disability; and the different time horizons based on empirical information from natural history data</td>
<td>$36,774 (£42,269) (10 years) (direct and indirect costs) $23,548 (£27,067) (all costs) $13,065 (£15,017) (20 years) (direct and indirect costs) $4,839 (£5,562) (all costs)</td>
<td>$34,516 (£39,674) to $60,484 (£69,522) (10 years) (direct and indirect costs) $22,097 (£25,399) to $50,645 (£58,213) (10 years) (all costs) $11,774 (£13,534) to $21,774 (£25,028) (20 years) (direct and indirect costs) $3,387 (£3,893) to $13,226 (£15,202) (20 years) (all costs)</td>
<td>Societal</td>
</tr>
<tr>
<td>Source</td>
<td>Treatment(s)</td>
<td>Methodology</td>
<td>Key Findings</td>
<td>Significance/Comparison</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>--------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Lepen et al (2000 prices)</td>
<td>IFNβ-1a in RRMS</td>
<td>Econometric model using 4-year data from the PRISMS study and projecting the data over 10 and 20 years. The model uses the AUC-EDSS as an integrated measure of disability to calculate the effectiveness of IFNβ-1a as number of EDSS months of disability saved.</td>
<td>Total cost £243,141 (€389,711) for 10 years = cost per EDSS-month £453 (€726). At 20 years, the total costs rose to £448,602 (€719,029) with the cost per EDSS-month saved reducing to £222 (€356).</td>
<td>Secondary analysis in the study confirmed that using a 1 dose of 44 µg rather than 3 doses of 22 µg per week saved 15 EDSS-months over 10 years = £1,400 (€22,440) per EDSS-month saved.</td>
<td></td>
</tr>
<tr>
<td>Touchette et al (2000 prices)</td>
<td>IFNβ-1b and Mitoxantrone in SPMS and PRMS</td>
<td>Using existing published data including the MIMS study, EUSPMS study and utility measures from Parkin et al; a Markov model was populated using EDSS level 3 as an entering point. The patients' disease progression was then followed for 10 years with the cost-utility measured as cost per QALY.</td>
<td>Compared with routine supportive care (4.9650 QALYS over 10 years costing $46,331 (€46,009)) IV MH resulted in 5.0860 QALYS costing $53,378 (€53,007). IFN produced a QALY of 5.1702 with a cost estimate of $115,833 (€115,028).</td>
<td>From a societal perspective, IV MH came out at $378,464 (€375,833) with IFN remaining the most costly at $433,932 (€430,916). When compared with routine supportive care, the IV MH resulted in a cost-utility ratio of $58,272 (€57,867) per QALY. Seen from the societal perspective, IV MH was less costly and produced bigger QALY gains.</td>
<td></td>
</tr>
<tr>
<td>Lazzaro et al (2006 prices)</td>
<td>IFNβ-1b for all CDMS</td>
<td>Incorporates the patients enrolled in the BENEFIT study into a 25 year epidemiological model and measures the cost of treatment of IFNβ-1b from the diagnosis of CIS compared to the cost of treatment once conversion to CDMS has happened.</td>
<td>The QALYs gained achieved statistical significance with the 7.84 QALY gained for the CIS arm, compared to 7.49 for the untreated arm. Early treatment of IFNβ-1b is cost effective when seen from the health service point of view with the ICER of €2,574.94 falling well below the acceptable incremental QALY range of €12,000 to €60,000.</td>
<td>Health perspective – €67,469 to €152,177 per QALY gained. €47,686 to €132,988 from societal perspective</td>
<td></td>
</tr>
<tr>
<td>Guo et al (2006 prices)</td>
<td>IFNβ-1a in RRMS</td>
<td>DES populated with data mainly taken from the EVIDENCE trial. The use of the DES model, over the more commonly used Markov model was to utilize the flexibility of a DES model when comparing various treatment scenarios.</td>
<td>The total mean costs per patient (discounted) were US$79,890 with SC IFNβ-1a, compared with US$74,485 with IM IFNβ-1a. However, even though this means an increase of US$5,405 per patient, SC IFNβ-1a was estimated to save 23 relapse-free days per patient or an incremental cost-effectiveness ratio of US$10,755 per relapse prevented.</td>
<td>SC IFNβ-1a estimated to prevent 0.50 relapses = 23 relapse-free days per patient = ICER of $10,755 per relapse prevented = $232 per relapse-free day gained</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Author</th>
<th>Intervention and disease category</th>
<th>Design, methods and timescales</th>
<th>Cost per QALY estimate</th>
<th>Sensitivity analysis (best-case and worse-case scenarios)</th>
<th>Perspective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gani et al</td>
<td>Natalizumab (Tysabri) in RRMS</td>
<td>Uses previously published data including efficacy data from the AFFIRM study to populate a 30-year Markov model developed based on a previous model by Chilcott et al</td>
<td>Natalizumab results in the most cost-effective ICER of $2300 (€3,348) per QALY gained. This is in comparison with IFNβ's ICER of £2000 (€2,911) and glatiramer acetate's ICER of £8200 (€11,937) per QALY gained. With a WTP threshold set at £10,000 (€14,557) per QALY, the probability of natalizumab being cost-effective are 72%, 71% and 59%. At a threshold of £30,000 (€43,671) per QALY, this increases to 89%, 90% and 94%</td>
<td>The authors suggest that natalizumab for patients with HARRMS is more cost-effective than interferon-b, glatiramer acetate and best supportive care if the societal WTP is higher than £8200 (€11,937) per QALY or £26,000 (€37,849) per QALY from the health perspective</td>
<td>Societal</td>
</tr>
<tr>
<td>Kobelt et al</td>
<td>Natalizumab (Tysabri) in RRMS</td>
<td>Uses existing literature (AFFIRM, Ontario data set and cost data from 2 previous Swedish studies to populate the Markov model to cover a 20-year time frame</td>
<td>From a health perspective natalizumab's total costs are €352,175 with a cost per QALY of €38,000</td>
<td>When seen over 20 years from the societal perspective, the total cost of natalizumab is €609,850 (€3830 less than standard care) with a cost per QALY dominating</td>
<td>Societal</td>
</tr>
<tr>
<td>Bell, et al</td>
<td>IFNβ and glatiramer acetate in RRMS</td>
<td>A Markov model populated by data from the literature was developed to assess the cost-effectiveness of 5 treatment strategies for RRMS patients compared to symptom management alone. The model incorporated the EDSS scale with 7 specific transition health states with the time horizon set at 13 years (approximation of a patient's lifetime with MS)</td>
<td>SC GA patients saw greater cost benefits with the incremental cost per QALY of $258,465 (€190,552) compared to $337,968 (€249,165), $416,301 (€306,916) and $310,691 (€229,056) for the IFNβ treatments respectively</td>
<td>Total costs for the lifetime of a patient were calculated at $295,586 (€217,919) for symptom management arm and $352,760 (€260,071), $364,267 (€268,554), $377,996 (€278,676) and $358,909 (€264,309) for each drug arm respectively. When direct medical costs were compared, the added costs of drug treatment were partially offset by cost savings in MS related medical costs. The SC GA arm saw the highest cost offset with 24% saved compared to 17%–22% cost saved by beta-interferons</td>
<td>Societal</td>
</tr>
<tr>
<td>Iskedjian et al</td>
<td>IFNβ-1a and Avonex in CDMS</td>
<td>A Markov model was designed to generate both the time spent in the pre-CDMS state (MLY) and QAMLY for the CEA and CUA perspectives</td>
<td>From the MoH perspective, the incremental cost-effectiveness of Avonex per MLY gained was CANS$3,110 (€37,658). In the CUA, the cost per QAMLY gained was CANS$277,586 (€161,371). From the societal perspective, the CEA ratio was CANS$44,789 (€31,758) per MLY gained and CANS$189,286 (€134,214) per QAMLY gained</td>
<td>$44,789 (€31,758) to $227,586 (€161,371)</td>
<td>Healthcare sector + Societal</td>
</tr>
</tbody>
</table>
A state transition model was developed with a 10-year treatment duration. The main outcome for the model was net QALY gains and ICER QALY gains.

From base case analysis, IFNβ-1a provided more health benefits and resulted in an ICER of $1,838,000 (€1,575,088)/QALY for men and $2,218,000 (€1,900,732)/QALY for women. Increasing the model to 40 years, the ICER for IFNβ-1a decreased to $250,000 (€214,239)/QALY for women and $235,000 (€201,385)/QALY for men.

40-year model – $250,000 (€214,239)/QALY for women and $235,000 (€201,385)/QALY for men or 10-year model $1,838,000 (€1,575,088)/QALY for men and $2,218,000 (€1,900,732)/QALY for women.

**Cost-effectiveness and cost-utility analysis by drug**

This paper focuses on recent additions to the literature and develops the base established in a previous review, but in order to provide a suitable context, a brief discussion of "older" studies and their limitations is presented below.

**Abbreviations:** AUC-EDSS, area under the EDSS time curve; CEA, cost-effectiveness analysis; CEU, cost-utility analysis; CDMS, clinically definite MS; CIS, clinically isolated syndrome; DES, discrete-event simulation model; EDSS, Expanded Disability Status Scale; GA, glatiramer acetate; HARRMS, highly active relapsing-remitting multiple sclerosis; ICER, incremental cost-effectiveness ratio; IFNβ-1a, interferon beta-1a; IFNβ-1b, interferon beta-1b; IM, intramuscular; MH, mitoxantrone hydrochloride; MLY, monosymptomatic life years; MS, multiple sclerosis; QALY, quality adjusted life-year; RRMS, relapsing-remitting MS; SC, subcutaneous; SPMS, secondary progressive MS; WTP, willingness to pay.
2 trials by the IFBN Multiple Sclerosis Study Group with patient, cost and quality of life data collected from questionnaires administered (EQ-5D and MSQOL). When discounted at 6%, IFNβ-1b was shown to reduce relapse by 1.52 per patient (over 5 years) giving a cost-effectiveness ratio of £28,700 (US$44,428) per relapse avoided. With a QALY gain of 0.054, this gave a cost-utility ratio of £809,900 (US$1,253,725) per QALY gained. Allowing for effects of progression over 5 years, the QALY gained reduces to £328,300 (US$508,208). Parkin’s study cited the lack of severe EDSS scores and no indirect costs as limitations of the study. However, new EDSS states were added in for the 1999 update to give a “range of different EDSS levels”. In this update, new data were also collected for costs and QOL with the patients split into two groups: patients who had suffered a relapse in the last 6 months and those who had not. A decision analytic model was then constructed using EDSS health states to calculate both the cost-effectiveness and cost-utility. The authors concluded that IFNβ-1b produces short-term QOL gains in patients with RRMS, however, the QALY gains are small and thus “the benefits are achieved only with a large additional cost”.

Studies that employed a societal perspective have, on occasions, produced more favorable cost-effectiveness ratios. For example, Forbes et al’s 1999 study evaluated the cost-utility of IFNβ-1b in SPMS in 132 ambulatory patients studied from a healthcare sector perspective but employed a societal perspective in the sensitivity analysis. The cost per QALY gained, from a healthcare perspective was estimated to be £1,024,393 (US$1,602,509) with a 95% confidence interval of £276,191 (US$432,059) to £1,484,824 (US$2,322,784). From a societal perspective, the authors claim the cost per QALY gained reduced by “only 0.2%” to around £1,022,344 (US$1,679,507). The authors concluded that it was “probably appropriate to allocate more resources to people with secondary multiple sclerosis, but access to IFNβ-1b should be restricted.” Kendrick et al’s 2000 study examined the CE of long term IFNβ-1a, and set out to challenge the assumptions of the clinical and cost benefit of IFNβ-1a used in previous CE studies. The model estimated the rate of disability progression in the RRMS patients receiving either IFNβ-1a or standard care (ie, without DMDs) and was extrapolated to produce annual EDSS scores for a period of 20 years. Results of the model showed high disease progression within the placebo arm (progression to EDSS stage II by 4 years from start of study) compared to patients receiving IFNβ-1a (progression to stage II by 11 years) Further extrapolation showed the same sets of patients progressing to stage III by 9 and 20 years respectively. Total costs per QALY (discounted at 6%) ranged from £27,000 (US$42,237) to £38,000 (US$59,445) depending on the length of IFNβ-1a treatment. Once societal costs (all costs including both direct and indirect) were included in the model, it was claimed that treatment of RRMS with IFNβ-1a could provide “substantial” cost savings to society, increasing with treatment duration. Phillips et al cited the similar assumptions and lack of ability to “closely reflect clinical practice” in the study. However, this study, which followed Parkin’s data and model closely, also considered the impact on indirect costs in the analysis to obtain a wider societal perspective and arrived at a more favorable cost-effectiveness ratio.

The next section summarizes and discusses more recent studies grouped by the disease modifying therapy.

**Interferon**

A US study by Guo et al examined the clinical and economic effectiveness of the treatment of RRMS using high-dose/high frequency subcutaneous (SC) IFNβ-1a, compared with low-dose weekly intramuscular (IM) IFNβ-1a. The study was performed from the US Payer’s perspective with a discrete event simulation model (DES) populated with data mainly taken from the EVIDENCE trial. The use of the DES model, over the more commonly used Markov model, was designed to utilise its flexibility when comparing various treatment scenarios, with the authors arguing that a Markov model “forces a disease into a few mutually exclusive states within a fixed time”, eg, fixed EDSS stages. The model simulated 1000 pairs of patients over a 4 year timeframe. Discounting was calculated annually at 3% beyond the first year. The total mean costs per patient (discounted) were US$79,890 (€67,477) with SC IFNβ-1a, compared with US$74,485 (€62,912) with IM IFNβ-1a. However, even though this means an increase of US$5405 (€4,565) per patient, SC IFNβ-1a was estimated to save 23 relapse-free days per patient – an incremental cost-effectiveness ratio (ICER) of US$10,755 (€9,084) per relapse prevented and US$232 (€196) per relapse-free day prevented. The authors estimated that there was a 95% probability that the cost per relapse prevented would be below US$20,000 and the cost per relapse-free day would be below US$420. They concluded that based on 1000 replications of the 1000 pairs of patients from the EVIDENCE trial, SC IFNβ-1a would have greater health benefits over 4 years than IM IFNβ-1a. However, this study had a limited time duration and did not include indirect costs in the analysis. Further, the cost-effectiveness was
measured in relation to relapses prevented and relapse-free days and therefore make it difficult to gauge the relative cost-effectiveness compared with other products.

Ikedjian et al’s 2005 Canadian study estimated the cost-effectiveness of Avonex® (IFNβ-1a) compared with current treatment of clinically definite multiple sclerosis (CDMS) following a single demyelinating event (SDE). The study performed both a cost-effectiveness (CEA) and cost-utility analysis (CUA) from the societal and healthcare sector perspectives. A Markov model was designed to generate the time spent in the pre-CDMS state (monosymptomatic life years (MLY)) and quality adjusted monosymptomatic life years gained (QAMLY) for the CEA and CUA perspectives respectively. Clinical data on the progression to CDMS was derived from the CHAMPS study and a 1989 Canadian study. Costs were derived from two Canadian cost of illness (COI) studies. The time horizon was set at 12 years by doubling the projected median time (6 years) a patient on Avonex would progress to the CDMS state. This enabled the authors to analyze the outcomes of the majority of the patients who suffered an SDE. The time horizon for the CUA model was 15 years. This was the median time for progression to CDMS state (6 years) added to the median time of progression to EDDS 3 (approximately 7 years). Outcomes at 20 and 30 years were captured through sensitivity analysis. From the Ministry of Health (MoH) perspective, the incremental cost-effectiveness of Avonex per MLY gained was CAN$53,110 ($37,658). In the CUA, the cost per QAMLY gained was CAN$27,586 ($161,371). From the societal perspective, the CEA ratio was CAN$44,789 ($31,758) per MLY gained and CAN$189,286 ($134,214) per QAMLY gained. The results of this study are favorable towards both the clinical and cost-effectiveness of Avonex for patients experiencing an SDE. Additionally, the authors suggest that the overall incremental cost-effectiveness of Avonex increases if treatment is administered pre-CDMS.

Kobelt et al’s 2003 study employed a Markov model to estimate the cost-effectiveness of IFNβ-1b treatment in patients with RRMS or SPMS. The study aimed to address how “treatment affects disease progression from diagnosis to severe disability”. Using clinical data from two 5-year trials, natural history data and cost-utility data, Kobelt’s study was performed from both the healthcare sector and societal perspective in Sweden. The model used the EDSS scale to define disease parameters and captures a mix of patients with both RRMS and SPMS according to the level of exacerbations suffered. The model consisted of 40 cycles (10 years) that is four 3-month cycles per year, with the IFNβ-1b intervention lasting 12 cycles (3 years) discounted at 3%. Mean total costs in the placebo arm amounted to €399,200 with the intervention €400,700. Cost per QALY gained was €7,800 (after 12 cycles). However, QALY gained increased to €38,700 with IFNβ-1b when treatment was increased to 54 months, and with potential cost savings being evident in the more severe states for the same time scale. At a willingness to pay (WTP) threshold of €50,000, the probability that IFNβ-1b was cost-effective was around 80%, which would increase to 90% at a WTP threshold of €80,000. The sample contains an SPMS subgroup combined with an RRMS subgroup from a differing trial as the authors had selected these due to their disease progression, rather than on relapse rate. Therefore the analysis supported the authors’ hypothesis that there is a larger treatment effect the more active the disease. Kobelt’s study claimed that the combination of RRMS and SPMS patients from two separate studies might result in a population of two groups that “were not fully comparable”. The issue of non-compliance in the clinical trials was also highlighted as a factor that might artificially improve the cost-effectiveness—a problem also seen in other studies.

Kobelt et al’s 2000 study estimated the cost-effectiveness of treatment of SPMS with IFNβ-1b. Using data from a population-based observational study, a Markov model was developed to estimate the incremental cost per QALY for treatment with IFNβ-1b compared with no treatment. Taking a Swedish societal perspective, the model was based on a 10 year time horizon (in cycles of 3 months) with Markov states based on EDSS measurements. The mean total cost of a relapse was estimated to be SEK 25,700 (€2,714). For the base case, the incremental QALY gain over 10 years was SEK 55,500 (€5,862) resulting in a cost per QALY of SEK 342,700 (€36,194) (including all costs). When indirect costs were excluded, the cost per QALY increased to SEK 542,000 (€57,243). Employing a cost-effectiveness threshold of US$60,000 (€51,418), the vast majority of cost-utility ratios were either below or equal the threshold.

Kobelt’s 2002 study used an adapted version of the Markov model described above, populated with natural history data of MS based on the London, Ontario study. The inclusion of these data was to reflect more accurately disease progression rather than using progression rates from clinical trial data which could result in potential bias. The model had 6 disease progression steps as opposed to the seven the earlier model. Using the same Swedish cost data, and discounting at 3%, this cost-utility analysis produced cost of care savings of SEK 177,400 (€18,736), of which SEK 11,600 (€1,225)
were due to relapse reduction. When all costs (including indirect costs) were included, the potential savings were SEK 150,300 (€15,874). The QALY was also estimated at SEK 257,200 (€27,164) in the base case. The authors attributed the higher cost-utility ratio of SEK 542,000 (€57,243) compared with the previous study to “the underestimate of the progression of disability”.

The study concluded that the cost per QALY falls below the threshold of US$30,000 (€25,709) “that in previous studies has been accepted as cost-effective in Sweden”.

Lazzaro et al’s 2009 study is the most recent economic evaluation of IFNβ-1b in the treatment of MS, the cost of treatment of IFNβ-1b from the diagnosis of clinically isolated syndrome (CIS) was compared to the cost of treatment once conversion to clinically definite MS (CDMS) has happened, from the Italian healthcare sector and societal perspectives. The study incorporated the patients enrolled in the BENEFIT study into a 25-year epidemiological model. From the healthcare sector perspective, the annual IFNβ-1b treatment costs per patient amounted to €7,150, €19,105 and €32,767 for the CIS, RRMS and SPMS patients respectively. IFNβ-1b was the major cost driver for CIS patients, with hospital admissions being the largest cost component for RRMS and SPMS patients. Conversely, from the societal perspective, the annual cost of treatment rose to €7,307, €25,349 and €45,841 for the CIS, RRMS and SPMS patients respectively. The cost drivers for the CIS patients were again the cost of IFNβ-1b. However, the major cost drivers for both the RRMS and SPMS patients were loss of working days combined with patient and family resources. The QALYs gained achieved statistical significance (P < 0.0001) with 7.84 QALYs gained for the CIS arm, compared to 7.49 for the untreated arm. The authors concluded that early treatment of IFNβ-1b was cost-effective from the healthcare sector point of view with an incremental cost-effectiveness ratio (ICER) of €2,575 falling well below the unofficial acceptable incremental QALY range of between €12,000 and €60,000. The study also suggested that early treatment of CIS with IFNβ-1b would significantly reduce disease progression to CDMS thus making it cost-effective in the long term.

A 2003 study by Lepen et al used econometric modeling of the 4 year data from the PRISMS study and, using the area under the EDSS-time curve (AUC-EDSS) as an integrated measure of disability, calculated the effectiveness of IFNβ-1a as number of EDSS-months of disability saved. By projecting the data over 10 and 20 years, the authors hypothesized that because the model would produce “real cost-effectiveness results in terms of cost per EDSS month of disability prevented”, it may be more “valid and more clinically meaningful than cost-utility ratios”. Cost data was derived from Murphy et al’s 1998 cost of illness study. The model reported that after 10 years, the IFNβ-1a arm experienced 484 EDSS-months of disability compared to 605 for the placebo arm. For 20 years, these figures increased to 1266 and 1587 respectively. For the UK, the total cost of care (including standard care and IFNβ-1a treatment) was £243,141 (€389,711) for 10 years. This gave a cost per EDSS-month of £453 (€726). At 20 years, the total costs rose to £448,602 (€719,029) with the cost per EDSS-month saving reduced to £222 (€356). The authors concluded that maintaining the patient at their current EDSS level reflected the increasing economic benefit of IFNβ-1a. Secondary analysis in the study confirmed that using a one dose of 44 µg rather than three doses of 22 µg per week saved 15 EDSS-months over 10 years, giving a cost of £14,000 (€22,440) per EDSS-month saved. However, the authors acknowledged the limitation of using the AUC measure as “a patient with a period of improvement followed by deterioration might have the same AUC as one who showed deterioration followed by improvement”. This, the authors add, may lead to “erroneous disability projections” if modeled over 20 years.

**Glatiramer acetate**

In 2001, Bose et al estimated the cost-effectiveness of glatiramer acetate in the treatment of RRMS using clinical data from the pivotal clinical trial for Copaxone combined with published cost and natural history data. The EDSS states used ranged from 0 to 7. The perspective was from the healthcare sector so no indirect costs were included. The cost per relapse, calculated from Parkin, was £2,362 (€3,786). Base case estimates for both 6 and 8 years demonstrated that cost-effectiveness improved as the time horizon lengths with £13,626 (€21,840) and £11,000 (€17,631) cost per relapse avoided respectively. Cost per disability unit avoided was estimated at £11,935 (€19,130) and £8,862 (€14,204) for 6 and 8 years respectively. When the duration of a relapse was one month instead of two, the cost per QALY over 8 years was £64,636 (€103,600). Further, after discounting at 6%, the cost per relapse avoided was £12,092 (€19,381), with cost per QALY being £24,870 (€39,862). Differential discounting (6% on costs and 1.5% on benefits) resulted in the cost per relapse at 8 years being £10,184 (£16,323) and cost per QALY £20,929 (£33,545). Finally, when indirect and informal costs were added (by doubling the cost per relapse to £4,724 (£7,572)) the cost per relapse avoided declined from £11,000 (£17,631) to £8,632 (£13,836), and cost per QALY declined to £17,733 (£28,423) in the base case.
However, in terms of the cost-effectiveness of glatiramer acetate, Bose used natural history data to fill in a gap where clinical data was not available for the placebo arm patients beyond 35 months. Finally, in terms of the cost per QALY ratio being driven by utility loss associated with relapse, the authors conclude that analysis “would have been improved with more robust data”.

Natalizumab

The study by Gani et al examined the cost-effectiveness of natalizumab (Tysabri) compared with IFNβ, glatiramer acetate and best supportive care in patients with highly active RRMS (HARRMS). Using previously published data, including efficacy data from the AFFIRM study, a 30-year model was developed from a societal perspective, based on a previous study by Chilcott. Of the 3 disease modifying treatments, natalizumab resulted in the most cost-effective ICER of £2,300 (£3,348) per QALY gained, compared with IFNβ’s ICER of £2,000 (£2,911) and glatiramer acetate’s ICER of £8,200 (£11,937) per QALY gained. Sensitivity analysis showed that the cost-effectiveness of natalizumab reduced when the timeline horizon was reduced to 20 years. When viewed from the healthcare sector perspective, the cost-effectiveness also fell. With a WTP threshold set at £30,000 (£43,671) per QALY, the probability of natalizumab being cost-effective was 89%, 90% and 94% respectively compared to IFNβ-1b, glatiramer acetate and best supportive care (BSC) respectively. In conclusion, the authors suggested that natalizumab for patients with HARRMS was more cost-effective than IFNβ, glatiramer acetate and best supportive care if the societal WTP was higher than £8,200 (£11,937) per QALY gained. If considering non compliance, the authors acknowledged the limitations linked to the combining of RRMS and SPMS patients from the AFFIRM study and the London Ontario dataset, while they did not include all indirect costs and also experienced the same uncertainty as Kobelt when considering non compliance.

Kobelt et al’s 2008 study modeled the cost-effectiveness of natalizumab compared with current practice. Employing a Swedish healthcare sector and societal perspective, Kobelt’s study used existing literature – AFFIRM, Ontario data set and cost data from 2 previous Swedish studies – and developed a model that covered a 20-year time frame with effects and costs discounted at 3%. The total cost of natalizumab was €609,850, €3,830 less than standard care, with a cost per QALY dominating, thus representing a best case scenario. The cost of natalizumab was €352,175 with a cost per QALY of €380,000, from the healthcare sector perspective. From the societal perspective, natalizumab was dominant in 55% of cases and the probability that the cost per QALY was < €50,000 was 75%. The authors concluded that for the population data used and from a societal perspective, “natalizumab provides an additional health benefit at a similar cost to current DMDs”.

Both these studies suffered from uncertainties, while Kobelt et al also expressed concern that all the RRMS patients started at EDSS 3.5. Additionally, the open-label extension of the AFFIRM study was stopped due to the appearance of progressive multifocal leukoencephalopathy in 2 patients, all of which resulted in Kobelt et al concluding that the “analysis has to be treated with caution”.

Thus even with newer therapies the uncertainties relating to their respective uncertainties remain.

Comparison studies of disease modifying therapies

Interferon and glatiramer acetate

Bell et al’s 2007 study compared the cost-effectiveness of 4 immunomodulatory drugs: SC glatiramer acetate and 3 IFNs: IM IFNβ-1a, SC IFNβ-1a and SC IFNβ-1b. A Markov model populated by data from the literature was developed to assess the cost-effectiveness of 5 treatment strategies for RRMS patients compared to symptom management alone. The model incorporated the EDSS scale with 7 specific transition health states with the time horizon set at 13 years (approximation of a patient’s lifetime with MS) and was measured from the US societal perspective. Total costs for the lifetime of a patient were calculated at US$295,586 ($217,919) for symptom management arm and US$352,760 ($260,071), US$364,267 ($268,554), US$377,996 ($278,676) and US$358,509 ($264,309) for each drug arm respectively. When direct medical costs were compared, the additional costs of drug treatment were partially offset by cost savings in MS related medical costs. The SC glatiramer acetate arm had the largest cost offset with 24% saved compared to 17% to 22% cost saved by beta IFNs. Overall, the SC glatiramer acetate patients received greater cost benefits with the incremental cost per QALY of US$258,465 ($190,552) compared to US$337,968 ($249,165), US$416,301 ($306,916) and US$310,691 ($229,056) for the 3 IFNβ treatments respectively. The authors concluded that all 4 drug treatments were associated with increased benefits for RRMS patients compared to symptom treatment alone, with SC glatiramer acetate being best strategy.

Prosser et al compared the cost-effectiveness of 3 immunomodulatory drugs (IFNβ-1a, IFNβ-1b and glatiramer acetate)
for newly diagnosed non-PPMS, compared with no treatment. A state transition model was developed with a 10-year treatment duration from the societal perspective. Costs were discounted at 3% per year. From base case analysis, IFNβ-1a provided more health benefits and resulted in an ICER of US$1,838,000 (€1,575,088)/QALY for men and US$2,218,000 (€1,900,732)/QALY for women. With 10-year treatment of IFNβ-1a, this resulted in gains of 11 QALYs for men and 13 for women. IFNβ-1b proved to be less effective and more costly than the no treatment. Glatiramer acetate had a higher ICER, but lower cost compared to IFNβ-1b. When treatment duration was varied to 40 years, the ICER for IFNβ-1a decreased to US$250,000 (€214,239)/QALY for women and US$235,000 (€201,385)/QALY for men.

This study demonstrated the significance of treatment duration on the relative cost-effectiveness of the therapies. “No treatment” for treatment duration of ≤6 years was found to be the most clinically and cost-effective option as treatments associated with side effects “outweighed the benefits of treatment”. Glatiramer acetate was found to be the most effective treatment between 6 and 9 years duration, whilst treatment of IFNβ-1a was found to be most effective for 10 years or more. The authors concluded that IFNβ-1a was the “best strategy in terms of health outcome”. However, the study suffered from assumptions made due to lack of information on the age at onset, relapse frequency or type of symptoms at onset of disease presented major limitations which the authors argued could affect the favorability of cost-effectiveness ratios.

In an evaluation of the cost-effectiveness of 4 DMDs in the treatment of RRMS and SPMS,98 3 IFNβs and glatiramer acetate were compared to no treatment in a 20-year model, with cost per QALY being the main outcome measure. Using data from the literature, the model simulated the clinical course of MS by using 10 point EDSS health states (RRMS from point 0 to 10; SPMS from point 2 to 10). IFNβ-1a 6 MIU/week (Avonex) proved to be the most cost-effective at £97,636 (€156,493) per QALY gained. The least cost-effective was glatiramer acetate with 20 mg/week (Copaxone) at £97,636 (€156,493) per QALY gained. The probability that any of the interventions would be less than a WTP threshold of £20,000 (€32,056) was between 3% and 18%. Due to the uncertainty surrounding the point estimates of cost-effectiveness, the authors suggested further research to establish the actual benefit derived from the treatment – specifically delays in relation to disease progression. The authors also recommended “real data” on the progress of people once treatment has ceased.

Interferon and mitoxantrone
Touchette et al103 aimed to compare the cost-utility of IV MH and SC IFNβ-1b with routine supportive care in patients with progressive relapsing MS (PRMS) and SPMS. The IV MH was administered every 3 months compared to the IFN, which was administered every other day. A Markov model was populated using EDSS level 3 as an entering point (using existing published data including the MIMS study,91 EUSPMS study63 and utility measures from Parkin).100 Patients’ disease progression was followed for 10 years and the study was undertaken from both the insurer’s and societal perspectives, with data gathered from Olmsted County (MMSDPC study).120 IV MH resulted in 5.0860 QALYS costing US$53,378 (€53,007), compared with routine supportive care (4.9650 QALYS over 10-years costing US$46,331 (€46,009)). IFN produced a QALY of 5.17 with a cost estimate of US$115,833 (€115,028). From a societal perspective, IV MH was US$378,464 (€375,833) with IFN remaining the most costly at US$433,932 (€430,916). When compared with routine supportive care, the IV MH resulted in a cost-utility ratio of US$58,272 (€57,867) per QALY, and from the societal perspective, IV MH was less costly and produced larger QALY gains.

The cost-utility ratios for IFN were higher from both the insurer and societal perspective (US$338,738 (€336,383) and US$245,700 (€243,992) respectively, compared to routine care. The mean cost-utility ratio for IFNβ-1b relative to MH was US$741,044 (95% CIs: US$6,564,807, US$7,482,341) and likely to be less than US$100,000 on less than 1% of occasions. The authors concluded that from the insurers’ perspective, IV MH in patients with PRMS and SPMS with EDSS scores of between 3 and 6 was a cost-effective option. From a societal perspective it represented a cost saving. Conversely, IFN treatment was not seen to be cost-effective in the population with the results being sensitive to both the clinical and cost-effectiveness of IV MH. However, the analysis suffers from the same limitations as those in Parkin’s study100 with regard to the use of utility measures.

Discussion and conclusion
The evaluation of DMDs for the treatment of MS provides an excellent scenario for illustrating the complexities involved in attempting to integrate the evidence relating to effectiveness and resource utilization. A number of useful frameworks and matrices have been proposed. For example, interventions with cost-QALY ratios of between $4,839 (€5,562) and $32,258 (€37,078) were adjudged to be cost-effective when there was good clinical evidence
of their effectiveness,\textsuperscript{121} while this has been adapted more recently as an aide for decision-makers.\textsuperscript{122} Another issue is what actually is a reasonable indicator of cost-effectiveness? It has been argued, for example, that NICE is more likely to view a technology favorably, subject to other relevant factors, if it costs less that $48,387 (\texteuro{}55,617) per QALY,\textsuperscript{123} while the risk sharing scheme for MS treatments has a threshold of $58,065 (\texteuro{}66,741) per QALY.\textsuperscript{124} Other studies have suggested that a cost per QALY threshold of $50,000 (\texteuro{}57,471) is appropriate,\textsuperscript{125,126} while a survey of health economists has suggested a threshold of $60,000 (\texteuro{}68,966).\textsuperscript{110}

The papers discussed in this review represent the wealth of information available to decision makers in relation to DMDs in the treatment of MS. However, all papers have limitations associated with them, which mean that the conclusions derived from a review of cost-effectiveness studies of DMDs remain equivocal. Issues relating to model design,\textsuperscript{15,100,101,107,113} use of natural history data and, reliance on clinical data that are subject to a variety of interpretations have been common features of studies undertaken to date and have conspired to generate an evidence-base that is at best muddled and inconclusive.

Recent studies have benefited from more relevant and up-to-date data relating to disease progression\textsuperscript{15,83,92,96,98,99,102,111,113,118} and have generally produced more favorable cost-effectiveness ratios, which are reflected in the cost-effectiveness acceptability curves produced. It therefore may be reasonable to conclude that the cost-effectiveness of interventions improves when longer time perspectives are employed, and the models reflect the progression of disease experienced by patients.\textsuperscript{5,96} As well as the time horizon, the estimates are highly sensitive to the approach taken to discounting costs and benefits; the cost of the therapies; the costs of patient management; disease progression, with and without treatment, and what happens to patients when they stop treatment; the impact of MS on carers in terms of utility loss and costs incurred; the effect of non-responders and adverse events associated with the therapies; the relationship between disability levels and utility losses and the extent to which indirect costs are included.

In conclusion, it would appear that the balance of evidence suggests that DMDs for patients with MS are not cost-effective when measured against prevailing cost/QALY thresholds. However, more recent studies have tended to tilt this balance and demonstrated a trend in producing lower cost-effectiveness ratios, which are either within thresholds or are reasonably close to them. Further, the use of cost-effectiveness acceptability curves in more recent studies has also served to highlight the likelihood that DMDs can be viewed as representing value for money. As more appropriate, robust information becomes available over the lifetime of the disease and as greater numbers of patient histories become documented, it is to be hoped that the quantity and quality of evidence on the impact of the drugs on disease progression clarifies issues relating to the effectiveness of the treatments, which, in turn, can lead to more informed judgement to place alongside the evidence-base in relation to decision making.

In addition, there are currently several major trials looking at the efficacy of new DMDs such as alemtuzumab (Phase III), Fingolimod (Phase III), cladribine (Phase III) and the controversial cannabinoid Sativex (Phase I). Therefore, it seems timely that developments in the field of health economics will hopefully address the methodological difficulties associated with modeling disease progression in order to move towards a consensus relating to the extent to which DMDs in the treatment of patients with MS can be regarded as being cost-effective.

**Disclosures**
The authors report no conflicts of interest.

**References**


